News | April 03, 2026
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The move strengthens GBL’s clinical-stage presence in the United States
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
